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S250 Poster Session IStandard of care HCT requires the patient with SCD to be less
than 16 years of age and have an HLA-matched, SCD-free sibling.
However, only about 14% of children with SCD have such a sibling.
In-vitro fertilization combined with pre-implantation genetic diag-
nosis, known as in-vitro fertilization with therapeutic intent
(IVFTI), makes it possible for parents to select a compatible, unaf-
fected embryo to implant and carry to term.
European investigators have published the birth of matched,
SCD-free sibling donors via IVFTI, but in the United States it re-
mains unreported in the medical literature and appears underutil-
ized, begging the question of why this combination of therapeutic
procedures has not been more widely offered, performed, or re-
ported in the U.S. pediatric SCD community.
We interviewed 22 adult SCD patients and parents/caregivers of
pediatric SCD patients to better understand their attitudes toward
IVFTI and HCT, and the barriers that prevent use of these thera-
peutic procedures.
Most interviewees (20 of 22 subjects) believed that the benefits of
matched-sibling HCT to the child outweighed the risks.
Most interviewees (15) were unaware SCD could be cured by
HCT.
After learning about IVFTI, 14 interviewees were interested in
pursuing it. The vast majority of interviewees (19) believed that
IVFTI should be offered to all SCD families before their affected
child becomes HCT ineligible due to age.
Every interviewee (22) claimed that the cost of IVFTIwas a barrier
to access and that insurance coverage would increase IVFTI use.
Currently, IVFTI is not covered by a large number of insurance pro-
viders, including Medicaid.
Lack of information and high costs are twomajor barriers prevent-
ing children with SCD from benefiting from IVFTI.
Pediatric SCD patients’ lack of access to IVFTI and, therefore,
matched-sibling HCT demonstrates the extent to which healthcare
disparities plague the SCD community. As SCDprimarily affects Af-
rican-American and Latino children, most of whom subscribe to
Medicaid, the lack of awareness and underutilization of this available
combination of therapies is not only an issue of clinical importance,
but also one of social justice.247
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Objective: Severe acquired aplastic anemia (SAA) is a rare disease of
childhood. Matched related hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pediatric patients with SAA.
Immunosuppressive therapy is the alternative treatment in children
with SAA who do not have a donor. We retrospectively analyzed pe-
diatric patients who received allogeneic HSCT from HLA-matched
related donors at our institution.
Methods: Between March 1993 and October 2009, 36 patients (12
female, 24 male) below 15 years old with multitransfused SAA re-
ceived allogeneic HSCT fromHLA-matched related donors (33 sib-
lings and 3 other relatives). Median age was 11 years (range 1 to 15
years). The graft source was bone marrow in 22 patients, peripheral
blood stem cells in 13 patients and 1 patient received both bonemar-
row and peripheral blood. All patients were conditioned with a mye-
loablative regimen containing cyclophosphamide, and
antithymocyte globulin. For graft-versus-host disease (GVHD) pro-
phylaxis, we used cyclosporine and methotrexate at the standard
doses.
Results: With a median follow-up of 30 months (range, 1-106
months), overall survival was 94% and was not statistically signif-
icant different between the patients receiving bone marrow trans-
plants and those receiving peripheral blood transplants. The
median time to neutrophil engraftment (absolute neutrophil
count .0.510^9/L) was +13 and median time to platelet en-
graftment (platelet count .2010^9/L) was +19. Grade III–IV
acute GVHD occurred in 7(19.4%) patients. The cumulative in-cidence of chronic GVHD for those who survived more than 100
days was 8.3%. 2-year disease-free survival was 83.3% and 2-year
overall-free survival was 94%. At present 30 of 36 patients are
alive with normal hematologic parameters and full donor chime-
rism and doing well. The number of patients who not engrafted
was 4 (11.7%) and mortality rate was 2(5.5%).The causes of
death included infection in both of patients.
Conclusions:These results confirm previous studies that condition-
ing with amyeloablative regimen allows for sustained engraftment of
HLA-matched related donor grafts in most multitransfused SAA pe-
diatric patients and is associated with low incidences of GVHD, low
toxicity, and long-term survival.248
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Background: Scoring systems based on pre-hematopoietic stem
cell transplant (HSCT) evaluation and co-existing morbidities
have been validated and used to assign risk of adverse outcome,
particularly for adult patients. Currently, there is no standard
method of re-assessing risk for those who have survived the acute
transplant period. Despite advances in supportive care, patients
remain vulnerable to death from both relapse and transplant-re-
lated mortality (TRM) beyond the 100 day mark. Platelet counts
are easily obtainable and routinely checked at post-HSCT visits.
We analyzed the platelet count 100 days post transplant to deter-
mine if values \100,000 are associated with increased mortality
in pediatric allogeneic HSCT patients.
Methods: Retrospective data on 161 consecutive patients undergo-
ing allogeneic HCST at Children’s Hospital Boston/Dana Farber
from 1/1/05– 8/1/08 were reviewed; we report on 143 of the151 pa-
tients alive at D100. Patient age/gender, diagnosis, donor, condi-
tioning and post-transplant complications (GVHD, relapse and
death) were collected. Patients ranged in age from 0.14 to 21 (median
9)years. 58% received transplants from an unrelated donor. All had
fully ablative transplants, 74% TBI based.
Results: Patients with platelet counts\100,000 at D100 had
a significantly increased risk of mortality (OR 2.21,p \0.0001).
Mean platelet count of those alive versus dead at any time after
100 days was 181,000 vs 101,000 (p\0.001) and mean platelet
count of those alive vs dead at 1 year post-HSCT was
177,000 vs 100,000 (p5.0002). TRM was strikingly increased
for patients in the low platelet group (OR16, p\0.0001). Those
dying from transplant-related causes had a mean platelet value of
65,000 at D100 compared to a mean value of 175,000 for those
who did not (p\0.001) The mean platelet count at D 100 was
not significantly different in patients who relapsed vs those who
did not.
Conclusion: Our results indicate that D100 platelet count has sig-
nificant prognostic value for subsequent mortality even though the
causes of thrombocytopenia in this setting are diverse. The increased
risk is primarily due to an increase in TRM in those with counts
\100,000. After D100 patients often have fewer physician visits
and care shared with non-HSCT providers. D100 platelet count is
a simple, inexpensive and reliable marker that can be used to identify
patients at risk for an adverse transplant outcome thus prompting
further evaluation and/or closer followup.249
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